AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2025-06-06T06:11:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Declining Stock and Decent Financials: Is The Market Wrong About EBOS Group Limited (NZSE:EBO)?
Wed 19 Mar 25, 03:02 AM3 Asian Dividend Stocks Yielding Over 3.1%
Tue 18 Mar 25, 04:01 AMEBOS Group (NZSE:EBO) Has Announced A Dividend Of A$0.5951
Sun 23 Feb 25, 08:30 PMEBOS Group First Half 2025 Earnings: EPS: AU$0.57 (vs AU$0.71 in 1H 2024)
Thu 20 Feb 25, 06:15 PMInvesting in EBOS Group (NZSE:EBO) five years ago would have delivered you a 104% gain
Thu 13 Feb 25, 09:23 PMIs There An Opportunity With EBOS Group Limited's (NZSE:EBO) 21% Undervaluation?
Sun 26 Jan 25, 08:02 PMEBOS Group Limited's (NZSE:EBO) Stock Is Going Strong: Is the Market Following Fundamentals?
Fri 04 Oct 24, 08:49 PMEBOS Group (NZSE:EBO) Ticks All The Boxes When It Comes To Earnings Growth
Fri 20 Sep 24, 06:15 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 406.39M | 327.37M | 282.60M | 246.23M | 201.94M |
| Minority interest | -10.96093M | 0.63M | -5.32100M | -4.07300M | -3.07100M |
| Net income | 275.74M | 224.64M | 199.09M | 173.95M | 173.95M |
| Selling general administrative | 578.28M | 467.06M | 382.43M | 347.69M | 357.61M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1698.92M | 1380.71M | 1066.34M | 987.11M | 846.26M |
| Reconciled depreciation | 135.80M | 90.78M | 78.05M | 78.29M | 33.54M |
| Ebit | 495.06M | 365.49M | 313.51M | 276.32M | 233.15M |
| Ebitda | 630.86M | 456.27M | 391.57M | 354.61M | 266.69M |
| Depreciation and amortization | 135.80M | 90.78M | 78.05M | 78.29M | 33.54M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 483.20M | 382.22M | 308.56M | 277.98M | 233.15M |
| Other operating expenses | 10402.47M | 9496.65M | 8072.80M | 7684.13M | 7012.38M |
| Interest expense | 73.79M | 25.44M | 22.18M | 25.32M | 28.52M |
| Tax provision | 119.69M | 103.35M | 84.85M | 68.54M | 56.29M |
| Interest income | 9.30M | 3.06M | 0.77M | 30.40M | 25.33M |
| Net interest income | -76.78855M | -31.80508M | -21.41184M | -23.83603M | -26.50555M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 119.69M | 103.35M | 84.85M | 73.36M | 58.89M |
| Total revenue | 13317.45M | 11901.67M | 9888.13M | 9381.93M | 7250.85M |
| Total operating expenses | 1199.92M | 985.25M | 748.81M | 704.39M | 607.80M |
| Cost of revenue | 11618.53M | 10520.96M | 8821.80M | 8394.82M | 6404.58M |
| Total other income expense net | -15.81891M | -36.28673M | -5.23155M | -3.95483M | -31.21050M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 286.70M | 224.01M | 197.75M | 172.87M | 143.05M |
| Net income applicable to common shares | 253.37M | 202.60M | 185.30M | 162.52M | 137.70M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 7368.95M | 7005.15M | 6945.94M | 4243.86M | 4010.26M |
| Intangible assets | 579.01M | 560.74M | 267.56M | 174.54M | 177.99M |
| Earning assets | - | - | - | - | - |
| Other current assets | 65.89M | 68.81M | 58.27M | 15.51M | 15.81M |
| Total liab | 4726.36M | 4498.50M | 4560.36M | 2733.49M | 2607.21M |
| Total stockholder equity | 2678.11M | 2649.25M | 2511.16M | 1516.09M | 1407.41M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 337.63M | 620.43M | 827.05M | 438.54M | 503.06M |
| Common stock | 2116.71M | 2056.66M | 2007.50M | 1067.60M | 1029.10M |
| Capital stock | 2116.71M | 2056.66M | 2007.50M | 1067.60M | 1029.10M |
| Retained earnings | 574.13M | 608.80M | 534.06M | 465.73M | 398.17M |
| Other liab | - | 284.94M | 327.90M | 138.89M | 140.11M |
| Good will | 2259.28M | 2150.80M | 2372.81M | 1073.75M | 1037.81M |
| Other assets | - | 208.60M | 182.16M | 141.84M | 0.00000M |
| Cash | 236.98M | 230.59M | 573.58M | 181.53M | 261.99M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3413.89M | 2892.65M | 2784.82M | 2017.81M | 1891.89M |
| Current deferred revenue | - | -98.61549M | -416.90041M | -163.86633M | -299.73289M |
| Net debt | 1558.22M | 1165.59M | 1253.23M | 549.45M | 603.88M |
| Short term debt | 899.20M | 100.41M | 414.84M | 164.54M | 300.51M |
| Short long term debt | 836.66M | 45.84M | 367.58M | 125.33M | 264.28M |
| Short long term debt total | 1795.20M | 1396.17M | 1826.82M | 730.98M | 865.87M |
| Other stockholder equity | 0.00000M | -2657.77601M | -2534.04824M | -1530.97452M | -1425.06670M |
| Property plant equipment | - | 660.67M | 576.98M | 464.94M | 402.42M |
| Total current assets | 3258.51M | 3272.26M | 3398.00M | 2282.85M | 2161.87M |
| Long term investments | 61.67M | 58.39M | 65.86M | 60.77M | 61.28M |
| Net tangible assets | - | -57.24000M | -116.53900M | 249.24M | 179.03M |
| Short term investments | - | 14.73M | 17.02M | -0.09330M | -0.09459M |
| Net receivables | 1633.05M | 1629.69M | 1524.26M | 1242.61M | 1094.50M |
| Long term debt | 513.66M | 1018.99M | 1160.06M | 347.66M | 324.92M |
| Inventory | 1322.60M | 1343.17M | 1241.88M | 843.19M | 789.57M |
| Accounts payable | 2177.06M | 2270.42M | 1959.83M | 1578.60M | 1388.05M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -12.72399M | -16.21395M | -30.39805M | -17.23971M | -19.85551M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 1029.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 37.67M | 19.17M | 1.51M | 0.03M | 0.35M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4110.43M | 3732.89M | 3547.94M | 1961.01M | 1848.40M |
| Capital lease obligations | 444.88M | 331.34M | 299.18M | 258.00M | 253.82M |
| Long term debt total | - | - | - | 527.19M | 528.22M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -167.88007M | -7.89600M | -0.49700M | -3.55100M | -0.11000M |
| Change to liabilities | 270.73M | 414.97M | 209.62M | 115.64M | 118.65M |
| Total cashflows from investing activities | -154.26500M | -1396.19700M | -113.76300M | -73.33100M | -120.05300M |
| Net borrowings | -450.61700M | 864.52M | -167.12000M | 7.44M | -51.87800M |
| Total cash from financing activities | -595.41952M | 1664.95M | -279.33383M | -79.97645M | 17.12M |
| Change to operating activities | 20.56M | 117.91M | 9.94M | 19.19M | 0.67M |
| Net income | 274.94M | 223.98M | 198.79M | 173.68M | 144.07M |
| Change in cash | -332.38655M | 386.25M | -81.47094M | 83.65M | 17.53M |
| Begin period cash flow | 562.97M | 187.33M | 263.00M | 178.34M | 156.80M |
| End period cash flow | 230.59M | 573.58M | 181.53M | 261.99M | 174.33M |
| Total cash from operating activities | 424.69M | 274.98M | 320.03M | 244.93M | 124.02M |
| Issuance of capital stock | 86.21M | 877.27M | 34.52M | 31.76M | 175.95M |
| Depreciation | 135.41M | 90.51M | 77.93M | 78.17M | 33.54M |
| Other cashflows from investing activities | - | - | -31.50300M | -44.05000M | -85.85200M |
| Dividends paid | -191.23953M | -170.87260M | -134.29247M | -119.69817M | 104.55M |
| Change to inventory | -141.34997M | -352.88971M | -50.48860M | -15.15585M | -188.43500M |
| Change to account receivables | -133.93751M | -240.55145M | -143.66219M | -133.36015M | 19.07M |
| Sale purchase of stock | 26.05M | 1287.16M | 53.29M | 43.49M | 168.18M |
| Other cashflows from financing activities | -53.30613M | -45.39417M | -37.88654M | -34.20422M | 24.14M |
| Change to netincome | 15.58M | -20.04200M | -18.20500M | -4.85800M | -2.58900M |
| Capital expenditures | 107.03M | 99.38M | 88.39M | 31.34M | 35.78M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -275.28749M | -593.44116M | -194.15079M | -148.51600M | 3.32M |
| Stock based compensation | 9.78M | 6.93M | 4.02M | 2.85M | - |
| Other non cash items | 14.34M | -39.51152M | 43.31M | -6.91642M | -177.61142M |
| Free cash flow | 317.66M | 175.59M | 231.65M | 213.59M | 88.24M |
Sector: Healthcare Industry: Medical Distribution
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EBO EBOS Group Ltd |
-0.5 1.42% | 34.70 | 26.87 | 26.45 | 0.57 | 2.79 | 0.67 | 14.86 |
| SIG Sigma Pharmaceuticals Ltd |
0.01 0.32% | 3.12 | - | 53.48 | 10.31 | 42.85 | 7.42 | 649.31 |
| PGC Paragon Care Ltd |
- -% | 0.38 | 38.00 | 5.98 | 0.19 | 2.10 | 0.20 | 11.81 |
| CYC Cyclopharm Ltd |
-0.03 2.78% | 1.05 | - | 116.28 | 4.25 | 2.81 | 3.91 | -24.5712 |
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. In addition, the company supplies health and wellness products to public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and provides pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers allografts solutions; healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
737 Bourke Street, Docklands, VIC, Australia, 3008
| Name | Title | Year Born |
|---|---|---|
| Mr. John Cullity | Chief Exec. Officer | NA |
| Mr. Leonard Hansen | CFO & Chief Accountant | NA |
| Ms. Andrea Bell | Chief Information Officer | NA |
| Martin Krauskopf | Exec. GM of Strategy, Mergers & Acquisitions and GM of Investor Relations | NA |
| Ms. Janelle Cain | Gen. Counsel | NA |
| Ms. Jacinta McCarthy | Group Gen. Mang. of HR | NA |
| Mr. Simon Bunde | Exec. Gen. Mang. of Strategic Operations, ESG & Innovation | NA |
| Ms. Julie Dillon | Chief Exec. Officer of Animal Care | NA |
| Mr. Matthew Muscio | Chief Exec. Officer of Medical Technology | NA |
| Mr. Brett Barons | Chief Exec. Officer of Symbion | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...